Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.022
Buy
RSI(14)
56.022
Neutral
STOCH(KDJ)(9,3,3)
39.406
Sell
ATR(14)
0.168
High Vlolatility
CCI(14)
2.914
Neutral
Williams %R
47.884
Neutral
TRIX(12,20)
2.140
Buy
StochRSI(14)
0.000
Oversold
Search
TELA Bio Inc
TELAAdd to Watchlist
0.971USD
+0.011+1.10%
Market hours （ET）Quotes delayed by 15 min
43.23MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of TELA Bio Inc
Currency: USD Updated: 2026-05-13Key Insights
TELA Bio Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
TELA Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
TELA Bio Inc Highlights
StrengthsRisks
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 37.33% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 80.28M.
Overvalued
The company’s latest PE is -1.22, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.85M shares, decreasing 15.76% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 128.70K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.07.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
2.250
Target Price
+131.93%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-13The current financial score of TELA Bio Inc is 6.74, ranking 117 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 19.06M, representing a year-over-year increase of 2.91%, while its net profit experienced a year-over-year increase of 8.96%.
Score
Financials
6.31
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.11
Operational Efficiency
6.39
Growth Potential
6.82
Shareholder Returns
7.08
TELA Bio Inc's Company Valuation
Currency: USD Updated: 2026-05-13The current valuation score of TELA Bio Inc is 8.30, ranking 30 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.22, which is -45.66% below the recent high of -0.66 and -303.10% above the recent low of -4.91.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 75/206
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-13The current earnings forecast score of TELA Bio Inc is 8.00, ranking 66 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 4.00, with a high of 5.00 and a low of 1.25.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
2.250
Target Price
+131.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
116
Total
6
Median
9
Average
Company name
Ratings
Analysts
TELA Bio Inc
TELA
5
Medtronic PLC
MDT
33
Stryker Corp
SYK
32
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-13The current price momentum score of TELA Bio Inc is 6.88, ranking 90 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.29 and the support level at 0.60, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.014
Sell
MA10
1.014
Sell
MA20
0.858
Buy
MA50
0.771
Buy
MA100
0.865
Buy
MA200
1.161
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-13The current institutional shareholding score of TELA Bio Inc is 7.00, ranking 80 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 73.39%, representing a quarter-over-quarter decrease of 2.93%. The largest institutional shareholder is James Simons, holding a total of 128.70K shares, representing 0.29% of shares outstanding, with 53.48% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-13The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TELA Bio Inc is 2.60, ranking 151 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. TELA Bio Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
1.27
VaR
+6.48%
240-Day Maximum Drawdown
+73.82%
240-Day Volatility
+129.57%
Return
Best Daily Return
60 days
+19.36%
120 days
+19.36%
5 years
+24.62%
Worst Daily Return
60 days
-15.70%
120 days
-15.70%
5 years
-37.18%
Sharpe Ratio
60 days
+1.27
120 days
+0.06
5 years
-0.53
Risk Assessment
Maximum Drawdown
240 days
+73.82%
3 years
+94.75%
5 years
+96.04%
Return-to-Drawdown Ratio
240 days
-0.40
3 years
-0.32
5 years
-0.19
Skewness
240 days
+0.45
3 years
-0.48
5 years
-0.35
Volatility
Realised Volatility
240 days
+129.57%
5 years
+87.89%
Standardised True Range
240 days
+13.40%
5 years
+37.12%
Downside Risk-Adjusted Return
120 days
+10.82%
240 days
+10.82%
Maximum Daily Upside Volatility
60 days
+120.38%
Maximum Daily Downside Volatility
60 days
+80.47%
Liquidity
Average Turnover Rate
60 days
+0.47%
120 days
+0.55%
5 years
--
Turnover Deviation
20 days
+7.37%
60 days
-22.91%
120 days
-9.17%
Peer Comparison
Healthcare Equipment & Supplies
TELA Bio Inc
TELA
6.87 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
BRKR
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
